top of page

Mylan lowballed Medicaid on EpiPen by $1.27B, far more than its DOJ settlement: HHS

Safi Bello

Fierce Pharma ------ Mylan quickly agreed to a $465 million settlement with the U.S. government last fall in a move to put some of its EpiPen problems in the past. Now, it appears that figure is far short of taxpayer harm resulting from the injector’s misclassification on Medicaid, news that comes as the deal has yet to be finalized. The Department of Health and Human Services’ Office of Inspector General reports that EpiPen’s Medicaid misclassification cost taxpayers $1.27 billion from 2006 to 2016, far exceeding the U.S. government’s settlement agreement with the drugmaker. Under heavy scrutiny for years of price hikes on the lifesaving epinephrine injection, Mylan struck a deal with the government to resolve fresh allegations of Medicaid misclassifications back in October. Investors cheered the move, because some had feared higher potential liabilities from the scandal. To learn more click on the picture below to read the article.

Mylan lowballed Medicaid on EpiPen by $1.27B, far more than its DOJ settlement: HHS - Read More from Fierce Pharma

 
 
Featured Posts
Recent Posts
Follow Us
  • Instagram
  • Pinterest
  • Tumblr Social Icon

© 2025 Safi Bello A Girls How To Guide

bottom of page